CTRI/2024/04/065084招募中3 期
A multicentric, randomized, prospective, double blind, parallel group, comparative, active controlled, phase III clinical study to evaluate the efficacy, safety and tolerability of Fixed Dose Combination of Dapagliflozin 10 mg and Telmisartan 80 mg versus concurrent use Dapagliflozin 10mg tablets and Telmisartan 80mg tablets in patients with Chronic Kidney Disease. - NI
ERIS LIFESCIENCES LIMITED0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing to give consent to participate
- •2. Female or male aged 18-65 (both inclusive) years at the time of consent.
- •3. Women of childbearing potential who comply to use an adequate method of contraception to avoid pregnancy throughout the study & who have a negative urine pregnancy test.
- •4. UACR more than 200 and less than 5000 mg/g at visit 1.
- •5. eGFR greater than 25 and less than 75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1.
- •6. Stable, and patient with maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated.
排除标准
- •1. Polycystic kidney disease, lupus nephritis or ANCA associated vasculitis.
- •2. Receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment.
- •3. History of organ transplantation.
- •4. Type 1 diabetes mellitus (T1D).
- •5. New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment.
- •6. MI, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.
- •7. Coronary revascularization (percutaneous coronary intervention PCI or coronary artery bypass grafting CABG) or valvular repair/replacement within 12 weeks prior to enrolment or is planned to undergo any of these procedures after randomization.
- •8. Any condition outside the renal and CV disease area, such as but not limited to malignancy, with a life expectancy of less than 2 years based on investigators clinical judgement.
- •9. Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma).
- •10. Hepatic impairment (aspartate transaminase AST or alanine transaminase ALT more than 3x the upper limit of normal ULN, or total bilirubin more than 2x ULN at time of enrolment).
- •11. Known blood-borne diseases.
- •12. Women of child-bearing potential (ie, those who are not chemically or surgically sterilised or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator OR women who have a positive pregnancy test at enrolment or randomization OR women who are breast feeding.
- •13. Participation in another clinical study with an IP during the last month prior to enrolment.
- •14. Inability of the patient, in the opinion of the investigator, to understand and or comply with IP, procedures and or followup OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.
研究者
相似试验
已完成
3 期
PMZ-1620 for the treatment of stroke.CTRI/2019/09/021373Pharmazz India Private Limited158
招募中
4 期
sovateltide Injection for the treatment of acute cerebral ischemic strokeCTRI/2023/12/060404Pharmazz India Private Limited
已完成
3 期
A clinical trial to study the safety and efficacy of 2mg and 4mg of ZYH1 compared to placebo in hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VI)].CTRI/2009/091/000533Cadila Healthcare Limited300
进行中（未招募）
不适用
Clinical study to evaluate the efficacy and safety of Lower Back Comfort in patients with Lower Back AcheCTRI/2018/03/012822Sami Labs Limited
已完成
2 期
To Study the effect of PMZ-1620 in stroke patients.CTRI/2017/11/010654Pharmazz India Private Limited40